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Abstract  
BACKGROUND: The recent epidemiological and experimental evidence suggest possible 
antioxidant effect of carbocysteine in patients with chronic obstructive pulmonary disease (COPD).  
AIM: To assess efficacy and tolerability of carbocysteine in the management of stable COPD.  
METHODS: We performed an observational, non-randomized, open study (a real life study) 
including 87 patients with stable COPD (group B and D by combined COPD assessment) divided in 
two groups, examined group (EG) and control group (CG). All participants were treated with the 
regular treatment of the stable disease, but in the participants of the EG carbocysteine 1,500 mg 
daily was added to their regular treatment during the period of two months. The study protocol 
included completion of the COPD Assessment Test (CAT) and spirometric measurements at initial 
visit and at the end of the mentioned period.  
RESULTS: We found significantly lower mean value of the overall CAT score in the EG at the end 
of the study as compared to its mean value registered at initial visit (26.9 vs. 24.3; P = 0.007). In 
regard to certain CAT items, we found significantly lower values of the mean scores related to 
cough phlegm and sleep disturbances as compared to their mean scores at initial visit. In addition, 
the mean values of the overall CAT scores at initial visit and at the end of the study in controls were 
similar. In EG we found significantly higher mean value of the MEF 25-75 at the end of the study as 
compared to its mean value registered at initial visit (59.3% vs. 67.2%; P = 0.003). There was no 
significant difference in the mean values of other spirometric parameters at the end of the study as 
compared to their mean values at initial visit. In controls we registered similar values of all 
measured spirometric parameters at the end of the study as compared to their values registered at 
initial visit. Mild gastrointestinal manifestations were registered in 13.3% of the participants of the 
EG during the examined period.  
CONCLUSION: Our findings indicate positive effects of carbocysteine regarding the symptoms and 
lung function, as well as its good tolerability in the patients with stable COPD. 
 
 
Introduction 
 
Chronic obstructive pulmonary disease 
(COPD) represents one of the principal demands of 
the public health at global level due to high morbidity, 
early mortality, high date rates and significant costs to 
health systems. The projection of the Global Burden 
of Disease Study indicates that COPD in 2020 will be 
the third leading cause of death worldwide (from sixth 
in 1990) and fifth leading cause of years lost 
(disability-adjusted life years - DALYs) through early 
mortality or handicap (12th in 1990) [1]. The health 
costs related to COPD are significant. Namely, in the 
European Union, the total direct costs of respiratory 
disease is estimated to be about 6% of the total health 
care budget, with COPD accounting for more than a 
half of this cost (38.6 billion Euros) [2]. 
The management of COPD, including 
management of stable disease and management of 
exacerbations, is a matter of growing interest and 
importance, and not a little controversy. According to 
the actual recommendations of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) the 
management of a stable disease is based on the 
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classification of the COPD patients in four groups (A, 
B, C and D) based on the combined assessment of 
the disease. The COPD patients from the groups A 
and C are characterized by fewer symptoms than 
patients from the groups B and D. In addition, the 
COPD patients from the groups A and B are 
characterized by mild or moderate airflow limitation 
and low risk of exacerbations, whereas the patients 
from the groups C and D are characterized by severe 
or very severe airflow limitation and high risk of 
exacerbations. Personalized pharmacological 
treatment based on combined assessment of the 
disease is considered as an optimal treatment of 
stable COPD [3, 4]. 
Carbocysteine, i.e. S-Carboxymethyl-L-
cysteine, is a mucolytic that reduces the viscosity of 
sputum allowing its easily bringing up. As a mucolytic 
it is used for a period of time in respiratory diseases 
characterized by hypersecretion of viscose mucus, 
such as acute bronchitis and exacerbations of chronic 
bronchitis, COPD and bronchiectasis [5]. Due to the 
antioxidant properties of carbocysteine and other 
mucolitics (i.e. free radicals scavenging and anti-
inflammatory effects), several studies investigated the 
possibility for their use in the management of stable 
COPD [6, 7, 8]. 
The aim of the present study was to assess 
efficacy and safety of carbocysteine in the 
management of stable disease in Group B and Group 
D COPD patients.  
 
 
Methods 
 
Study design and setting 
An observational, non-randomized, open 
study (i.e. real life study) was performed at the 
Institute for Occupational Health of R. Macedonia, 
Skopje - WHO Collaborating Center and GA
2
LEN 
Collaborating Center in the period March – November 
2015. The efficacy and tolerability of two months 
treatment with carbocysteine was assessed in the 
groups B and D of patients with stable COPD by 
assessment of their symptoms (i.e. the impact of the 
disease on their health status) and lung function at 
initial visit and at the end of the study. 
 
Study subjects 
The study population included 87 subjects 
divided in two groups: examined group (EG) and 
control group (CG).  
EG included 45 patients with stable COPD of 
both genders, aged 44 to 74 years classified by the 
combined COPD assessment into Group B and Group 
D. The exclusion criteria were: patients classified as 
Group A and Group C COPD patients, patients with 
another respiratory disease (e.g. bronchial asthma, 
bronchiectasis, pneumonia, cystic fibrosis, etc); 
exacerbations occurred during the study period, 
known hypersensitivity to carbocysteine, patients who 
did not retain sufficient capacity for normal conduction 
of the study, and serious adverse effects during the 
treatment with carbocysteine. 
The study subjects from EG besides the 
regular treatment of stable disease were treated with 
carbocysteine 1,500 mg daily (2 capsules 
carbocysteine 375 mg twice daily) in the period of two 
months. In addition, 42 Group B and Group D COPD 
patients matched to the patients from EG by sex and 
age were studied as controls. During the study period 
the controls were treated with their regular treatment 
of stable COPD.  
All participants were informed about the study 
and their written consent was obtained. 
 
Study protocol 
The study protocol included collection of 
demographic characteristics, completion of the COPD 
Assessment Test (CAT) and lung function 
measurements.  
Demographics of the study subjects were 
collected by questionnaire at initial visit. All study 
subjects completed the COPD Assessment Test 
(CAT) at initial visit and at the end of the study. 
Furthermore, spirometric measurements including 
measuring of forced vital capacity (FVC), forced 
expiratory volume in 1 second (FEV1), FEV1/FVC ratio 
and maximal expiratory flow at 25 to 75% of the vital 
capacity (MEF25-75), were performed in all study 
subjects at initial visit and at the and of the study. 
 
Completion of the questionnaire for 
demographic characteristics 
Demographics of the study subjects, including 
sex, age, smoking status, body mass index (BMI), 
previous or current occupational exposure to noxious 
particles and gases, and comorbidities were collected 
by questionnaire at initial visit. 
Classification of smoking status of the study 
subjects was done by World Health Organization 
(WHO) recommendations [9]. Passive smoking or 
exposure to environmentl tobacco smoke was defined 
as an exposure to tobacco combustion products from 
smoking by others (at home, workplace, etc.), i.e. as a 
presence of at least one smoker in the household 
and/or in the workplace [10, 11].  
 
Completion of the CAT 
All study subjects completed the CAT at initial 
visit and at the end of the study.  
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The questionnaire consisted of 8 original CAT 
questions translated in Macedonian: 
 Q1 I never cough / I cough all the time; 
 Q2 I have no phlegm (mucus) in my chest at 
all / My chest is completely full of phlegm 
(mucus); 
 Q3 My chest does not feel tight at all / My 
chest feel very tight; 
 Q4 When I walk up a hill or one flight of stairs 
I am not breathless / When I walk up a hill or 
one flight of stairs I am very breathless; 
 Q5 I am not limited doing activities at home / I 
am very limited doing activities at home; 
 Q6 I am confident leaving my home despite 
my lung condition / I am not at all confident 
leaving my home because of my lung 
condition; 
 Q7 I sleep soundly / I don’t sleep soundly 
because of my lung condition; 
 Q8 I have lots of energy / I have no energy at 
all. 
Each question had score ranging from 0 to 5 
points (0 = no impairment). An overall CAT score was 
derived as a sum of the scores for each response. It 
may range from 0 to 40 providing a measure of the 
impact of the disease on a patient’s health status. The 
overall CAT scores more than 30 and more than 20 
indicate very high and high impact of COPD on 
patient’s health status, respectively. The overall CAT 
score ranging from 10 to 20 indicates medium impact, 
the overall CAT score less than 10 indicates low 
impact of the disease on the patient’s health status, 
whereas the overall CAT score of 5 represents the 
upper limit of normal in healthy non-smokers [12]. 
 
Spirometry 
Spirometric measurements were performed in 
all study subjects at initial visit and at the end of the 
study by spirometer Ganshorn SanoScope LF8 
(Ganshorn Medizin Electronic GmbH, Germany) with 
recording the best result from three measurements 
the values of FEV1 of which were within 5% of each 
other. The results of spirometry were expressed as 
percentages of the predicted values. Interpretation of 
the results was based on the actual recommendations 
of European Repsiratory Society (ERS) and American 
Thoracic Society (ATS) [13, 14]. 
 
Statistical analysis 
The quantitative variables were expressed as 
mean values with standard deviation (SD), whereas 
the qualitative variables as absolute frequencies and 
percentages. The comparison of the mean scores of 
the particular CAT questions, as well as the mean 
overall CAT scores was done by Student’s t-test. The 
comparison of the mean values of measured 
spirometric parameters was also done by Student’s t-
test. A P-value less than 0.05 was considered as 
statistically significant. Statistical analysis was 
performed using the Statistical Package for the Social 
Sciences (SPSS) version 11.0 for Windows.  
 
 
Results 
 
Study subjects from both groups have similar 
demographic characteristics (Table 1). 
Table 1: Demographic of the study subjects 
Characteristic EG 
(n = 45) 
CG 
(n = 42) 
M/F ratio 
Mean age (years) 
Mean BMI 
1.4 
58.3  7.6 
25.6  3.1 
1.4 
57.4  8.4 
25.8  2.7 
Smoking status 
Active smokers 
Ex-smokers 
Passive smokers 
Occupational exposure to dusts or gases 
(current or former) 
Mean duration of the disease (years) 
Combined assessment of the disease 
Group B 
Group D 
Management of the stable disease  
Monotherapy with LA bronchodilator 
LA 2-agonist 
LA anticholinergic 
Combined therapy 
Combination LA 2-agonist + ICS 
Combination LA 2-agonist + LA anticholinergic + ICS  
Comorbidities 
Arterial hypertension 
Osteo-muscular disorders 
Diabetes type 2 
Ishaemic heart disease 
 
14 (31.1%) 
8 (17.7%) 
9 (20.0%) 
21 (46.7%) 
 
10.7  3.3  
 
23 (51.1%) 
22 (48.9%) 
 
23 (51.1%) 
9 (20.0%) 
14 (31.1%) 
22 (48.9%) 
12 (26.6%) 
10 (22.2%) 
29 (64.4%) 
12 (26.7%) 
10 (23.2%) 
7 (15.5%) 
4 (8.9%) 
 
11 (26.2%) 
8 (19.1%) 
10 23.,8%) 
18 (42.8%) 
 
9.2  3.8  
 
23 (54.7%) 
20 (45.3%) 
 
23 (54.7%) 
8 (19.1%) 
15 (35.7%) 
20 (45.3%) 
10 (23.8%) 
10 (23.8%) 
25 (59.5%) 
12 (28.6%) 
12 (28.6%) 
5 (11.9%) 
5 (11.9%) 
Data are presented as n, mean  SD, or n (%). M: male; F: female; BMI: body mass index; 
LA: long-acting; ICS: inhaled corticosteroid.  
 
The mean scores for each CAT question at 
initial visit in EG varied from 3.0 for Q3 to 3.8 for Q2, 
whereas the mean scores for each CAT question at 
the end of the study varied from 2.8 for Q3 to 3.3 for 
Q2. Statistically significant reduction in the mean 
scores at the end of the study as compared to the 
mean scores at initial visit was registered for Q1, Q2 
and Q7.  
Table 2: Mean scores for each CAT question and overall CAT 
mean score registered in EG at initial visit and at the end of the 
study 
Mean score 
 
At initial visit 
At the end  
of the study 
 
P - value 
Q1 
Q2 
Q3 
Q4 
Q5 
Q6 
Q7 
Q8 
Overall CAT score 
3.6  0.5 
3.8  0.4 
3.0  0.6 
3.1  0.4 
3.2  0.3 
3.3  0.5 
3.5  0.4 
3.4  0.3 
26.9  4.2 
3.1  0.4 
3.3  0.3 
2.8  0.4 
2.9  0.6 
3.1  0.4 
3.2  0.7 
3.0  0.5 
3.2  0.7 
 24.3  4.6 
0.000 
0.000 
0.066 
0.062 
0.183 
0.437 
0.000 
0.082 
0.006 
Data are presented as mean  SD. CAT: COPD Assessment Test. 
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The mean scores registered at the end of the 
study for Q3, Q4 and Q8 were lower than then their 
values registered at initial visit, but the difference was 
not statistically significant, whereas the values of 
mean scores registered for Q5 and Q6 at the end of 
the study were similar to their values registered at 
initial visit. In addition, the overall CAT mean score 
registered at the end of the study was significantly 
lower than its value registered at initial visit (Table 2).   
Significant improvement of the overall CAT 
mean scores in EG was registered in both Group B 
and Group D COPD patients (18.3 vs. 13.2; P = 0.017 
and 32.7 vs. 29.1; P = 0.023, respectively) (Figure 1). 
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Figure 1: Overall CAT mean scores registered in Group B and 
Group C COPD patients 
  
The mean scores for each CAT question, as 
well as the overall CAT score, registered in controls at 
initial visit were similar to their values registered at the 
end of the study (Table 3).  
Table 3: Mean scores for each CAT question and overall CAT 
mean score registered in controls at initial visit and at the end 
of the study 
Mean score At initial visit 
At the end  
of the study 
 
P - value 
Q1 
Q2 
Q3 
Q4 
Q5 
Q6 
Q7 
Q8 
Overall CAT score 
3.7  0.6 
3.8  0.3 
2.9  0.4 
3.0  0.3 
3.2  0.4 
3.2  0.4 
3.3  0.3 
3.3  0.4 
26.4  3.1 
3.6  0.5 
3.7  0.6 
3.0  0.4 
3.1  0.5 
3.1  0.3 
3.2  0.6 
3.2  0.4 
3.2  0.5 
 26.2  3.8 
0.409 
0.337 
0.255 
0.269 
0.198 
1.000 
0.198 
0.315 
0.792 
Data are presented as mean  SD. CAT: COPD Assessment Test. 
 
The mean values of FVC, FEV1 and 
FEV1/FVC registered in EG at initial visit were lower 
than their values registered at the end of the study, 
but the difference is not statistically significant. The 
mean value of MEF25-75 registered at initial visit was 
significantly lower than its mean value registered at 
the end of the study (Table 4). 
 
 
Table 4: Mean values of spirometric parameters in EG 
registered at initial visit and at the end of the study 
Spirometric parameter At initial visit 
At the end  
of the study 
 
P - value 
FVC 
FEV1 
FEV1/FVC 
MEF25-75 
72.2  7.8  
47.6  8.9 
0.61  0.04 
59.3  9.6 
73.8  6.7 
49.7  6.3 
0.62  0.02 
67.2  10.1 
0.300 
0.200 
0.137 
0.003 
Data are presented as mean  SD. FVC: forced vital capacity; FEV1: forced expiratory 
volume in 1 second; MEF25-75: maximal expiratory flow at 25 to 75% of the vital capacity. 
 
The mean values of FVC, FEV1, FEV1/FVC 
and MEF25-75 registered in controls at initial visit were 
similar to their mean values registered at the end of 
the study (Table 5). 
Table 5: Mean values of spirometric parameters in controls 
registered at initial visit and at the end of the study 
Spirometric parameter At initial visit 
At the end  
of the study 
 
P - value 
FVC 
FEV1 
FEV1/FVC 
MEF25-75 
70.9  9.4  
46.3  8.1 
0.60  0.06 
60.2  12.7  
70.1  11.3 
47.4  9.4 
0.61  0.04 
61.7  11.2 
0.725 
0.567 
0.371 
0.567 
Data are presented as mean  SD. FVC: forced vital capacity; FEV1: forced expiratory 
volume in 1 second; MEF25-75: maximal expiratory flow at 25 to 75% of the vital capacity. 
 
The frequency of adverse effects in the EG 
during the study period was 13.3%. Mild 
gastrointestinal manifestations (nausea, vomiting, and 
epigastric pain) which did not require discontinuation 
of the treatment were registered in six patients. 
 
 
Discussion 
 
Oxidative stress and chronic inflammation are 
key features in the COPD pathogenesis. Oxidative 
stress plays an important role in several elements of 
the lung physiology and the development of COPD, 
such as oxidative inactivation of antiproteases and 
surfactants, mucus hypersecretion, membrane lipid 
peroxidation, alveolar epithelial injury, and remodeling 
of extracellular matrix. Therefore, targeting oxidative 
stress with antioxidants may be effective in the 
treatment of stable COPD [15-21].  
The aim of the present study was to assess 
efficacy and tolerability of carbocysteine in patients 
with stable COPD. According to the actual GOLD 
recommendations, pharmacological treatment of 
stable COPD is classified as recommended first 
choice, alternative choice and other possible 
treatments. Carbocysteine is recommended as other 
possible treatment for Group D COPD patients [3]. In 
addition, according to the actual recommendations of 
Leicestershire Medicines Strategy Group (LMSG), 
carbocysteine is recommended in the treatment of 
stable COPD in the patients with expressed chronic 
cough and sputum production (i.e. COPD patients 
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classified in groups B and D) [22].  
The study population in present study 
included 87 patients with stable COPD classified by 
combined assessment of the diseases into groups B 
and D. The study subjects were divided in two groups 
regarding the treatment with carbocysteine besides 
the regular treatment of the disease. In both groups 
there was a large proportion of active and passive 
smokers, as well as a low proportion of ex-smokers, 
that was similar to their prevalence in general 
population documented in our previous studies [23, 
24]. These findings suggest insufficient anti-smoking 
activities, i.e. they indicate a need of improvement of 
the control of tobacco use in R. Macedonia. According 
to the results of studies on smoking status conducted 
in developed countries, e.g. New Jersey Adult 
Tobacco Survey and Australian National Health 
Survey, in the countries with more effective anti-
smoking strategies there is a significantly lower 
prevalence of active and passive smokers and 
significantly higher prevalence of ex-smokers as 
compared to their prevalence registered in our studies 
[25, 26]. 
We found significant reduction of the impact 
of COPD on health status in the study subjects from 
carbocysteine group after a period of two months due 
to improvement of majority symptoms of the disease 
assessed by CAT. Significant reduction was 
registered in mean scores for cough, phlegm and 
sleep disturbances at the end of the study as 
compared to their values at initial visit. Values of the 
mean scores for chest tightness and exercise 
tolerance at the end of the study obtained at the end 
of the study were also lower, but the difference was 
not statistically significant. In addition, in the study 
subjects from carbocysteine group we found 
significant reduction of the mean value of MEF25-75 
(i.e. index of the airflow in the small airways) at the 
end of the study as compared to its value at initial 
visit.  
The findings from other studies in this domain 
are somewhat inconsistent depending on their design, 
study population, daily dose of administered 
carbocysteine, period of administration, etc. Results 
from the double blind, placebo-controlled study 
including 709 patients with severe COPD carried out 
by Zheng et al. (PEACE Study) indicated significant 
improvement of quality of life assessed by St. 
George’s Respiratory Questionnaire for COPD 
Patients (SGRQ-C) and significant reduction of 
exacerbations after one year administration of 
carbocysteine 1,500 mg daily [27]. Similar results 
were obtained in the studies carried out by Tatsumi et 
al. and Yasuda et al. including COPD patients treated 
with carbocysteine 1,500 mg daily during one year 
[28, 29]. In addition, results of the study carried out by 
Esposito et al. suggested that daily administration of 
carbocysteine for prolonged period in addition to 
regular COPD treatment could be considered as a 
good strategy for reduction of exacerbation frequency 
[30]. Furthermore, results from several studies 
indicated that carbocysteine could restore steroid 
sensitivity in steroid insensitive pulmonary diseases 
and could improve the targets of regular treatment in 
patients with severe COPD [31, 32]. On the contrary, 
results of some studies indicated that administration of 
carbocysteine in COPD patients was associated with 
small overall benefits, i.e. that its use could reduce 
exacerbations with little or no effect on overall quality 
of life [33, 34]. Results from some studies indicated 
that treatment of stable COPD with carbocysteine was 
more effective in COPD patients not receiving inhaled 
corticosteroids in regard to reducing a frequency of 
exacerbations [27, 33, 34]. In the present study we did 
not assess the efficacy of carbocysteine in regard to 
frequency of exacerbations, but we found significant 
improvement of symptoms in patients who received 
and did not receive inhaled corticosteroids as their 
regular treatment. 
In the present study we found a low frequency 
of adverse effects in carbocysteine group, i.e. mild 
gastrointestinal manifestations which did not require 
discontinuation of the treatment. Similar findings were 
registered in the PEACE study [24].  
The findings of this study are subjects of at 
least three limitations. First, relatively small number of 
the study subjects could have certain implications on 
data obtained and its interpretation. Second, the study 
design could also have certain implications on data 
obtained and its interpretation. Third, relatively short 
period of treatment with carbocysteine do not enable 
to assess its effect on the frequency and severity of 
COPD exacerbations knowing that they have 
significant impact on the COPD course and 
progression. On the other study, the strength of the 
study is its observational design in regard to 
assessment of symptoms and lung function in a 
certain groups of COPD patients by standardized and 
validated questionnaire and spirometry before and 
after treatment with carbocysteine.  
In conclusion, in an observational, non-
randomized, open study aimed at assessment of 
efficacy and tolerability of carbocysteine in the 
management of stable COPD we found improvement 
of the symptoms and spirometric parameters 
reflecting airflow in the small airways in the group of 
COPD patients treated with carbocysteine in the 
period of two months. Our findings also indicate a 
need of further studies in this domain in order to 
obtain more effective management of COPD.  
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